Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation… Read more
Recursion Pharmaceuticals Inc (RXRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.112x
Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) has a cash flow conversion efficiency ratio of -0.112x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-117.36 Million) by net assets ($1.05 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Recursion Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Recursion Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Recursion Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Recursion Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Permanent TSB Group Holdings PLC
LSE:PTSB
|
0.044x |
|
OXFYY
PINK:OXFYY
|
N/A |
|
Genus plc
PINK:GENSY
|
N/A |
|
JL MAG RARE-EARTH H YC1
F:3KLA
|
N/A |
|
Shanghai Tunnel Engineering Co Ltd
SHG:600820
|
0.135x |
|
Nippon Life India Asset Management Limited
NSE:NAM-INDIA
|
0.003x |
|
Jiamei Food Packaging Chuzhou Co
SHE:002969
|
0.048x |
|
Chongqing Sanfeng Environment Group Corp Ltd
SHG:601827
|
0.081x |
Annual Cash Flow Conversion Efficiency for Recursion Pharmaceuticals Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Recursion Pharmaceuticals Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.03 Billion | $-359.17 Million | -0.347x | +44.10% |
| 2023-12-31 | $463.44 Million | $-287.78 Million | -0.621x | -261.18% |
| 2022-12-31 | $485.81 Million | $-83.52 Million | -0.172x | +41.15% |
| 2021-12-31 | $542.94 Million | $-158.61 Million | -0.292x | -232.75% |
| 2020-12-31 | $-206.29 Million | $-45.40 Million | 0.220x | -52.06% |
| 2019-12-31 | $-124.27 Million | $-57.04 Million | 0.459x | -- |